|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1996-11-5
|
|
pubmed:abstractText |
Tacrolimus (FK 506) was introduced into organ transplantation as a powerful immunosuppressive but with several adverse effects. In fact, an appropriate protocol for using this agent has not yet been established. On the basis of pharmacokinetic studies and the reports of its administration as a continuous intravenous infusion, we designed the regimen of every eight hours in order to reduce the daily dosage.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0919-8172
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
180-3
|
|
pubmed:dateRevised |
2006-10-30
|
|
pubmed:meshHeading |
pubmed-meshheading:8776613-Administration, Oral,
pubmed-meshheading:8776613-Adult,
pubmed-meshheading:8776613-Anti-Inflammatory Agents,
pubmed-meshheading:8776613-Diabetes Mellitus,
pubmed-meshheading:8776613-Dose-Response Relationship, Drug,
pubmed-meshheading:8776613-Female,
pubmed-meshheading:8776613-Graft Rejection,
pubmed-meshheading:8776613-Humans,
pubmed-meshheading:8776613-Hyperparathyroidism,
pubmed-meshheading:8776613-Immunosuppressive Agents,
pubmed-meshheading:8776613-Injections, Intravenous,
pubmed-meshheading:8776613-Kidney Diseases,
pubmed-meshheading:8776613-Kidney Transplantation,
pubmed-meshheading:8776613-Male,
pubmed-meshheading:8776613-Prednisolone,
pubmed-meshheading:8776613-Tacrolimus,
pubmed-meshheading:8776613-Tissue Donors
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation.
|
|
pubmed:affiliation |
Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase III
|
